Tempus AI (NASDAQ:TEM) Trading 3.5% Higher – What’s Next?

Tempus AI, Inc. (NASDAQ:TEM)’s share price shot up 3.5% on Friday . The stock traded as high as $49.40 and last traded at $49.72. 2,849,544 shares were traded during mid-day trading, a decline of 43% from the average session volume of 5,025,887 shares. The stock had previously closed at $48.04.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TEM. Wolfe Research lowered Tempus AI from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th. Piper Sandler cut their price target on Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Needham & Company LLC lifted their price target on Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Bank of America lifted their price target on Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Finally, Loop Capital cut their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and a consensus price target of $61.18.

Tempus AI Stock Up 4.6 %

The company has a 50 day simple moving average of $56.07 and a 200 day simple moving average of $51.45. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Insider Activity

In related news, COO Ryan Fukushima sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total value of $792,200.00. Following the transaction, the chief operating officer now directly owns 982,442 shares in the company, valued at approximately $38,914,527.62. This represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $60.00, for a total value of $826,200.00. Following the completion of the transaction, the chief accounting officer now owns 57,237 shares in the company, valued at $3,434,220. This represents a 19.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,598,969 shares of company stock worth $317,194,162 over the last ninety days.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TEM. Operose Advisors LLC acquired a new position in Tempus AI in the fourth quarter valued at approximately $25,000. First Horizon Advisors Inc. acquired a new position in Tempus AI in the third quarter valued at approximately $30,000. Farther Finance Advisors LLC acquired a new position in Tempus AI in the fourth quarter valued at approximately $34,000. Prestige Wealth Management Group LLC lifted its holdings in Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after acquiring an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC acquired a new position in Tempus AI in the fourth quarter valued at approximately $49,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.